Impact of Lowering Low-Density Lipoprotein Cholesterol with Contemporary Lipid-Lowering Medicines on Cognitive Function: A Systematic Review and Meta-Analysis
| Autor: | Zhida Shen, Meihui Wang, Binquan Zhou, Hangying Ying, Jiacheng Wang |
|---|---|
| Rok vydání: | 2020 |
| Předmět: |
0301 basic medicine
medicine.medical_specialty Subgroup analysis 030204 cardiovascular system & hematology law.invention 03 medical and health sciences Cognition 0302 clinical medicine Ezetimibe Randomized controlled trial law Internal medicine medicine Humans Pharmacology (medical) Randomized Controlled Trials as Topic Alirocumab Pharmacology business.industry Anticholesteremic Agents PCSK9 PCSK9 Inhibitors Cognitive disorder Cholesterol LDL General Medicine medicine.disease Evolocumab 030104 developmental biology Meta-analysis Hydroxymethylglutaryl-CoA Reductase Inhibitors Cardiology and Cardiovascular Medicine business medicine.drug |
| Zdroj: | Cardiovascular Drugs and Therapy. 35:153-166 |
| ISSN: | 1573-7241 0920-3206 |
| Popis: | To evaluate the potential association between the lowering of low-density lipoprotein cholesterol (LDL-C) with contemporary lipid-lowering medicines and cognitive function. Randomized controlled trials (RCTs) in databases including PubMed, Embase, and the Web of Science and all databases in the Cochrane Library and ClinicalTrials.gov were collected from inception to January 1, 2020. The cognitive function of patients receiving proprotein convertase subtilisin/kexin type 9 (PCSK9) inhibitors, statins and ezetimibe was evaluated using meta-analysis. A total of 2910 studies were obtained from databases and other sources. Thirty-three studies were selected by screening, including 11 studies on alirocumab, 9 studies on evolocumab, 11 studies on statins and 2 studies on ezetimibe. In our study, a total of 128,691 patients with no cognitive impairment were divided into an intervention group (66,330 patients) and a control group (62,361 patients). The data were subjected to a random-effects model or a fixed-effects model for meta-analysis. The contemporary lipid-lowering medicines significantly reduced LDL-C in terms of both percentage (WMD: −45.06%, 95% CI −50.12% to −40.00%, P |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|
Full text from SpringerLink